A Series B funding round has pulled in $22.1 million for Stat-Diagnostica, which the company said will be used to further develop its Near Patient Testing technology and conduct clinical trials. The diagnostic platform merges immunoassay and molecular methods into a single unit and takes less than 30 minutes to detect infectious diseases, antibiotic resistance and biomarkers.

Related Summaries